PARAMOUNT - Maintenance Pemetrexed

Update: 2025-10-03

Description

Our Landmarks of OncoPharm series returns to discuss PARAMOUNT, a landmark study that helped solidify the role of maintenance pemetrexed in NSCLC.

Comments

In Channel

PARAMOUNT - Maintenance Pemetrexed

2025-10-0311:09

SC Pembro, Biotin, 5-yr POLARIX data

2025-09-2518:00

ALASCCA

2025-09-2112:33

EGFRm NSCLC Updates

2025-09-1113:41

Time to Cilta-Cel-ebrate?

2025-09-0410:25

RNA Vaccine Potential as a Cancer Treatment

2025-08-2811:25

Venetoclax Dosing & APOLLO

2025-08-2117:47

Zongertinib

2025-08-1412:07

Dordaviprone & RCT to prevent ADRs

2025-08-0711:30

ProMACE-CytaBOM

2025-07-3110:21

Testicular Cancer in a Nutshell

2025-07-1711:19

Supportive Care Updates

2025-07-1011:12

Linvoseltamab & sunvozertinib

2025-07-0309:36

Antiandrogen Withdrawal

2025-06-2509:53

June 2025 Updates

2025-06-1927:37

ASCO 2025

2025-06-0514:15

CLEOPATRA

2025-05-2911:17

Talking about cancer misinformation

2025-05-2215:27

Four New Drugs

2025-05-2212:20

Mg to Prevent Cisplatin Kidney Injury

2025-05-0815:48

00:00

1.0x

PARAMOUNT - Maintenance Pemetrexed

#box-pro-ellipsis-175953878579037{-webkit-line-clamp:2;}PARAMOUNT - Maintenance Pemetrexed

PARAMOUNT - Maintenance Pemetrexed

John Bossaer

PARAMOUNT - Maintenance Pemetrexed